PT  - JOURNAL ARTICLE
AU  - Al-Banji, Muradi H.
AU  - Zahr, Doaa K.
AU  - Jan, Mohammed M.
TI  - Lennox-Gastaut syndrome
AID  - 10.17712/nsj.2015.3.20140677
DP  - 2015 Jul 01
TA  - Neurosciences Journal
PG  - 207--212
VI  - 20
IP  - 3
4099  - http://nsj.org.sa/content/20/3/207.short
4100  - http://nsj.org.sa/content/20/3/207.full
SO  - Neurosciences (Riyadh)2015 Jul 01; 20
AB  - Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3Hz) spike wave discharges on electroencephalography. Atonic seizures result in dangerous drop attacks with risks of injury and impairment of the quality of life. The seizures are frequently resistant to multiple antiepileptic (AED) drugs. Newer AEDs, such as rufinamide, are now available. When multiple AED trials fail, non-pharmacological treatments such as the ketogenic diet, vagus nerve stimulation, and epilepsy surgery, should be considered. The aim of this review is to present an updated outline of LGS and the available treatments. Although the prognosis for complete seizure control remains poor, the addition of newer therapies provides an improved hope for some of these patients and their families. Further long term randomized controlled trials are required to compare different therapeutic interventions in terms of efficacy and tolerability.